Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 9/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245328 | 0.82 | KCNH2 (0.44) | MTNR1BMTNR1A | |
| SCHEMBL3245332 | 0.82 | KCNH2 (0.44) | MTNR1BMTNR1A | |
| SCHEMBL5206013 | 0.80 | MTNR1A (0.49) | MTNR1BMTNR1A | |
| Hydrochloric Acid SCHEMBL7726049 | 0.79 | MTNR1A (0.48) | MTNR1BMTNR1A | |
| SCHEMBL3243038 | 0.79 | MTNR1B (0.51) | MTNR1BMTNR1AADAM17 | |
| Trifluoroacetic Acid SCHEMBL7726051 | 0.76 | MTNR1A (0.45) | MTNR1BMTNR1A | |
| Trifluoroacetic Acid SCHEMBL7728891 | 0.76 | MTNR1A (0.45) | MTNR1BMTNR1A | |
| SCHEMBL3252168 | 0.74 | CCR8 (0.46) | MTNR1BMTNR1A | |
| SCHEMBL3252171 | 0.74 | CCR8 (0.46) | MTNR1BMTNR1A | |
| SCHEMBL3252874 | 0.74 | KCNH2 (0.59) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799674-B1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
| EP-1799674-A1 | NEW PIPERIDINE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038172-A1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | MTNR1B 2247/4885MTNR1A 2634/4885ADAM17 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.